MorphoSys

Read more
Jean-Paul Kress's photo - CEO of MorphoSys

CEO

Jean-Paul Kress

CEO Approval Rating

83/100

Founded:

1992

Status:

PublicIndependent CompanyFRAMOR

Annual Revenue
$402.5M
Employees
615

MORPHOSYS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Jean-Paul Kress

CEO

- -
615
$457.7M
$402.5M
View Profile
1

CEO

- -
40,000
- -
$42.2B
View Profile
2

Jan G. J. van de Winkel

President & CEO

99/100
781
$639.9M
$1.7B
View Profile
3

Dolores J. Schendel

CEO

68/100
142
$251.2M
$9.8M
View Profile
4

CEO

- -
61
$76M
$34.5M
View Profile
5

CEO

- -
95
$106.9M
$7M
View Profile
6

Harpreet Singh

President & CEO

100/100
142
$361.3M
$38.4M
View Profile
7

Michael W. Nall

President & CEO

78/100
87
$41.3M
$43.8M
View Profile
8

Marco Londei

CEO

90/100
50
$7.8M
$2M
View Profile
9

Alan Wise

CEO

68/100
115
$12.2M
$4.7M
View Profile
10

Mark Erlander

CEO

- -
13
$50M
$ < 1M
View Profile

Missing a competitor? Contribute!

MorphoSys Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$402.5M

MorphoSys's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 9B. Over the last two quarters, MorphoSys's revenue has grown by 203.8%. Specifically, in Q4 2020's revenue was $78.2M; in Q3 2020, it was $25.7M.

MorphoSys Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Constellation Pharmaceuticals, Inc.

Jun 2021

Source »
$1.7B
Constellation is a Massachusetts-based biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of cancer.

MorphoSys Funding History

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Apr 2018
$207.8M
-
Equity
Nov 2016
$123.9M
-
Private Placement
Sep 2013
$126M
-

MorphoSys Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Adivo specializes in developing species-specific therapeutic antibodies for pet cancer and chronic inflammatory conditions.
-
Aug 19, 2018
Seed
-

MorphoSys News

MorphoSys Press Releases

MorphoSys Videos

Social Media

MorphoSys Headquarters

Semmelweisstr. 7

Planegg, Bavaria82152

49-89-899-27-0

Driving Directions »

Trending Companies

MorphoSys Summary

ABOUT

Overview

MorphoSys develops and commercializes therapeutic antibodies for the treatment of cancer, inflammatory and autoimmune diseases. MorphoSys was founded in 1992. MorphoSys' headquarters is located in Planegg, Bavaria, DE 82152. It has raised 457.7M in 3 ...

CEO

MorphoSys's CEO, Jean-Paul Kress, currently has an approval rating of 83%. MorphoSys's primary competitors are Janssen, Genmab & Medigene.

Frequently Asked Questions about MorphoSys

  1. When was MorphoSys founded?

    MorphoSys was founded in 1992
  2. Who is MorphoSys's CEO?

    MorphoSys's CEO is Jean-Paul Kress
  3. How much revenue does MorphoSys generate?

    MorphoSys generates $402.5M in revenue
  4. How much funding does MorphoSys have?

    MorphoSys has historically raised $457.7M in funding
  5. Where is MorphoSys's headquarters?

    MorphoSys's headquarters is in Planegg Bavaria, DE
  1. How many employees does MorphoSys have?

    MorphoSys has 615 employees
  2. What sector does MorphoSys operate in?

    MorphoSys is in Biotechnology
  3. Who are MorphoSys's competitors?

    MorphoSys's top competitors are Janssen, Genmab, Medigene
  4. Who has MorphoSys invested in?

    MorphoSys's has invested in companies such as Adivo